Table 2.
Endpoint | Independent prognostic factor(s) | p-Value | HR (95% CI) |
---|---|---|---|
LRC | Histology: WHO type II vs. III | 0.02 | 2.86 (1.16–7.14) |
DFFS | N stage: N0 vs. N+ | 0.045 | 0.28 (0.08–0.97) |
DFS | Age: ≤55 years vs. >55 years | 0.027 | 0.46 (0.23–0.92) |
EQD2,T: <64 Gy vs. ≥64 Gy | 0.037 | 2.08 (1.04–4.17) | |
OS | Age (years): ≤ 55 vs. >55 | 0.001 | 0.39 (0.23–0.68) |
LRC, loco-regional control; DFFS, distant failure-free survival; DFS, disease-free survival; OS, overall survival; EQD2,T, equivalent tumor dose; HR, hazard ratio; CI, confidence interval.